All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What are the challenges associated with CAR T-cell therapy in patients with AML?
Bookmark this article
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with chimeric antigen receptor T-cell therapy in patients with acute myeloid leukemia (AML)?
What are the challenges associated with CAR T-cell therapy in patients with AML?
Firstly, Tettamanti discusses some of the challenges in developing chimeric antigen receptor T-cell therapies for the treatment of patients with AML, such as identification of suitable target tumor-associated antigens, potential off-target toxicities, and lack of persistence resulting in relapse. She then highlights how the disease biology of AML and prior treatment can hinder the manufacturing process, and concludes by discussing novel strategies to overcome these challenges.
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox